China Medical System Holdings (CMS; HKG: 0867) announced an asset transfer agreement with Wuhan YZY Biopharma Co., Ltd, securing global rights to the latter’s tetravalent bispecific antibody (BsAb) targeting vascular endothelial growth factor (VEGF) and angiopoietin 2 (ANG2) for intravitreal injection. Financial terms were not disclosed.
Agreement Details
The deal encompasses all assets related to the BsAb, including intellectual property and rights owned by YZY Bio or its affiliates. CMS will assume full ownership of the product’s development and commercialization.
Product Profile
The Category 1 biologic, in pre-clinical development for fundus neovascular disease, features a unique nanobody design. It offers high affinity, strong inhibitory activity, high preparation concentration, good stability, and low administration frequency, reducing risks from frequent intravitreal injections and improving patient adherence.
Market Context
Mainland China has ~4 million neovascular age-related macular degeneration (AMD) patients and ~5 million diabetic macular edema (DME) patients. Anti-VEGF drugs are standard therapy for fundus neovascular disease, with China’s 2021 market size exceeding RMB 3.1 billion (USD 458 million).-Fineline Info & Tech
